Novartis agreed to pay $1.1 billion upfront to buy Myricx Bio, aiming to expand its antibody-drug conjugate pipeline with a payload approach described as differentiating from incumbent ADC classes. The deal provides Myricx’s NMTi payload platform and comes with milestone payments up to $400 million as described. The coverage highlights Myricx’s preclinical rationale that NMT inhibitor payloads may address resistance mechanisms and improve performance in solid tumor models. Lead candidates targeting B7-H3 and HER2 were described as key programs, positioning the platform where existing clinical benchmarks already validate the targets. For Novartis, the acquisition reflects continued interest in broadening ADC exposure beyond internal R&D and targeted radioligand efforts, while for the sector it signals sustained willingness to underwrite platform technology during competitive ADC patent landscapes.